Cannabis Science Initiates Preclinical Investigation of CS-TATI-1 for European Studies for Squamous/Basal Cell Carcinomas and Kaposi's Sarcoma

Concept Sheet Development for Cell Line Activity and Animal Model Pharmacokinetics for European Agency Review to be Initiated in 4Q

COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Sep 24, 2012 - Cannabis Science (NASD OTC: CBIS), a pioneering U.S. Biotech Company developing pharmaceutical products for global public health challenges, is pleased to announce preclinical investigations being initiated in Europe for Squamous/Basal Cell carcinomas and Kaposi's sarcoma based on inhibition of carcinogenicity utilizing cannabinoids that have been demonstrated in recent studies to significantly affect tumor necrosis.

The company is entertaining entrance into a number of agreements with academic and private sector clinical research organizations that will facilitate initial studies to demonstrate scientific merit of CSTATI-1 and CS-S/BCC-1 that will predictably translate to human studies within the coming year, as clinical options for this patient population remain limited and the etiology of both aggressive squamous/basel cell carcinomas and Kaposi's sarcoma is poor in immune compromised populations, comparative to other skin cancers.

“To match our U.S. efforts, we are aggressively pursuing institutional investigations abroad to take advantage of the significant expertise demonstrated in many academic research centers on cannabinoids to further our clinical investigation platform,” said Dr. Robert Melamede, President & CEO of Cannabis Science Inc., “we expect to generate from these collaborations a robust portfolio of preclinical data that supports the wide range of our scientific premises on the utility of cannabinoids for aggressive cancers for patients in desperate need of innovative clinical alternatives.”

The Company will update the public and its shareholders of the progress as peer-reviewed publication of the results of these preclinical investigations are made public.

About CS-S/BCC-1

Cannabis Science is currently working to develop preclinical investigations of CS-S/BCC-1 treatment of basal and squamous cell carcinomas.

About CS-TATI-1

Data published in March by researchers at the Mount Sinai School of Medicine found that cannabinoids inhibit TAT induced migration to TAT via cannabinoid 2 receptors (CB2). Funding for the Mount Sinai study was provided by a National Institutes of Health (NIH) Clinical and Translational Science Award Grant. Cannabis Science's research of CS-TATI-1 will be targeted to newly diagnosed patients infected with drug resistant virus, treatment experienced patients with drug-resistant HIV strains, and those intolerant of currently available therapies. Cannabis Science will be pursuing a wide range of NIH based Federal Research Programs such as RO1's, PO1's and SBIRS which exist to support preclinical development of target validation and proof of concept studies. Cannabis Science will be pursing implementation of these studies through collaborations with leading scientific institutions. Cannabis Science will also be pursuing other clinical research collaborations including the AIDS Clinical Trials Groups (ACTG), the Canadian AIDS Trial Network (CATN) and the European AIDS Trial Network (EATN).

About Cannabis Science, Inc.

Cannabis Science, Inc. is conducting cannabinoid research and development for unmet medical needs. The Company works with leading experts in HIV drug development, medicinal characterization, and clinical research to develop, produce, and commercialize Phytocannabinoid-based pharmaceutical products.

Cannabis Science is currently working with CBR International to develop a Pre-IND Application to the FDA that focuses on the use of CS-S/BCC-1 topical cannabis-based preparations for the treatment of basal and squamous cell carcinomas.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

 

Contact: Cannabis Science Inc.
Dr. Robert J. Melamede
President & CEO
1-888-889-0888
info@cannabisscience.com
www.cannabisscience.com
or
Robert Kane
VP of Investor Relations
1-561-234-6929
rkane@cannabisscience.com
info@cannabisscience.com
www.cannabisscience.com

 

 

Posted: September 2012

View comments

Hide
(web2)